The Therapeutic Goods Administration (TGA) is seeking comments from interested parties on the addition of proposed new advisory statements for labels of over the counter (OTC) and registered complementary medicines containing menthol for dermal use, for inclusion in the Required Advisory Statements for Medicine Labels (RASML). The proposal to include advisory statements for menthol in RASML follows previously implemented requirements for advisory statements on labels of menthol-containing listed medicines.
The TGA is requesting comments that will help ensure that the proposed advisory statements are appropriate and support the quality use of the medicines and that any label changes that would be required for these medicines are made in the most convenient, efficient and cost-effective way.
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Menthol
We invite you to provide your feedback by clicking 'Make a submission' below and responding to the consultation question (by free text and/or file upload).
Share
Share on Twitter Share on Facebook